Phase 4 Atrial Fibrillation Trial, Recruiting NCT02347111 Sponsor: University of Illinois at Chicago Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Phase 4 Atrial Fibrillation Trial, Recruiting

NCT02347111
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have a history of atrial fibrillation (an irregular heart rhythm) that comes and goes or is persistent, with symptoms occurring at least twice a month
  • People who have had a heart tracing (ECG) recorded within the past month that shows atrial fibrillation
  • People whose condition means they are medically suitable to take either of two specific heart rhythm medications — Flecainide (a Class I drug) and Sotalol (a Class III drug) — as determined by their treating doctor
  • People who are able to give their informed consent to participate

Who may not be able to join:

  • People whose atrial fibrillation is permanent, or who have only atrial flutter (a related but different heart rhythm condition)
  • People who have had heart or chest surgery in the past 6 months
  • People who have previously used the heart medication amiodarone for longer than a short period (for example, a brief hospital stay for an acute episode does not count)
  • People with a medical condition that is likely to be life-threatening within one year
  • People who have previously had a procedure to treat atrial fibrillation using ablation (a treatment that uses energy to correct the heart's electrical signals)
  • People who have already tried two or more heart rhythm medications for atrial fibrillation in the past
  • People whose kidneys are not filtering blood well enough (a kidney function measurement called creatinine clearance below 40 ml/min — confirm with trial site)
  • People whose heart is pumping at less than 50% of its normal capacity, as measured on a heart scan
  • People who have a reason they cannot take Class I heart rhythm medications — for example, those with structural heart disease or a history of heart attack
  • People who have a reason they cannot take Class III heart rhythm medications — for example, those with a heart electrical condition called long QT syndrome, or whose heart tracing shows a QTc measurement above 480 ms (females) or 460 ms (males) at the start of the trial (confirm with trial site)
  • People whose atrial fibrillation is caused by a treatable underlying condition, such as an overactive thyroid
  • People who are pregnant or breastfeeding
  • People who have a history of severe problems with the heart's electrical conduction system (called AV node dysfunction), unless they already have a pacemaker fitted
  • People whose close family member (parent, child, or sibling) has already taken part in this study
  • People who are not able to follow the study procedures required for research purposes

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 6158879032

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
University of Illinois at Chicago
Registry
ClinicalTrials.gov
Start date
31 December 2020
Est. completion
30 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

AF burden (Percent of time subject is in atrial fibrillation)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov